OncoMatch/Clinical Trials/NCT07398963
Clinical Study of Oncolytic Vaccinia VIrus Delivering Targeted CD19 in Vivo CAR-T/M Therapy for Refractory/Relapsed B-cell Lymphoma
Is NCT07398963 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies CD19-CAR novel oncolytic vaccinia virus for refractory/relapsed b-cell lymphoma.
Treatment: CD19-CAR novel oncolytic vaccinia virus — To study the safety and effectiveness of oncolytic Vaccinia VIrus-Delivered Targeted CD19 In Vivo CAR-T/M Therapy for Refractory/Relapsed B-Cell Lymphoma
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD19 positive (immunohistochemistry or flow cytometry)
CD19 positive (immunohistochemistry or flow cytometry)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: any systemic therapy
complete remission after 2 lines of therapy; Disease progression during any course of treatment, or disease stabilization time equal to and less than 6 months; or disease progression or recurrence within 12 months after autologous hematopoietic stem cell transplantation
Must have received: BTK inhibitor — MCL
MCL: Complete remission after 2 lines of treatment (including BTK inhibitors); Disease progression during any course of treatment, or disease stabilization time equal to and less than 6 months; or disease progression or recurrence within 12 months after autologous hematopoietic stem cell transplantation
Cannot have received: gene therapy
Receiving gene therapy or any type of oncolytic virus therapy within 3 months before the study treatment
Cannot have received: oncolytic virus therapy
Receiving gene therapy or any type of oncolytic virus therapy within 3 months before the study treatment
Lab requirements
Blood counts
absolute peripheral blood neutrophil ≥ 1000/mm3, platelet ≥ 50,000/mm3
Kidney function
creatinine <1.5mg/dl
Liver function
alt (alanine aminotransferase)/ast (aspartate aminotransferase) less than 2.5 times the upper limit of normal; total bilirubin < 1.5 mg/dl
Cardiac function
cardiac ejection fraction (ef) ≥ 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07398963 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior gene therapy, oncolytic virus therapy disqualifies patients from enrollment.
Does this trial require CD19?
Yes, CD19 positive (immunohistochemistry or flow cytometry) is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages